Shares in Germany's Bayer have plunged after a U.S. jury found the Roundup weed killer was a substantial factor in a California man's cancer — the second case that has gone against manufacturer Monsanto, acquired by Bayer last year.
Bayer AG shares dropped 13 percent to 60.66 euros ($68.84) in Frankfurt Wednesday. On Tuesday, a federal court jury in San Francisco ruled unanimously in a lawsuit against Monsanto. Attorneys say the trial, which will determine in a second phase whether the company is liable and if so, for how much, could help determine the fate of hundreds of similar lawsuits.
Monsanto says studies have established that Roundup's active ingredient, glyphosate, is safe. It has appealed a separate U.S. court decision last year in favor of a man who used Roundup.
A recent meta-analysis by researchers at the University of Washington found being “highly exposed” to glyphosate — found in common weed killers like Roundup — increases a person’s cancer risk by 41 percent.
“Our analysis focused on providing the best possible answer to the question of whether or not glyphosate is carcinogenic,” senior author Lianne Sheppard, a professor in the UW departments of Environmental & Occupational Health Sciences and Biostatistics, said in a press release. “As a result of this research, I am even more convinced that it is.”
Support real journalism. Support local journalism. Subscribe to The Atlanta Journal-Constitution today. See offers.
Your subscription to the Atlanta Journal-Constitution funds in-depth reporting and investigations that keep you informed. Thank you for supporting real journalism.